New combo therapy aims to stop pancreatic cancer return after surgery
NCT ID NCT07632118
First seen Jun 16, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Participants receive either chemotherapy alone or chemotherapy plus targeted radiation, and researchers track how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin medical university hospital and institute
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy plus gemcitabine and capecitabine chemotherapy
What this could lead to
If successful, this could establish a new standard treatment to reduce recurrence and improve survival for high-risk pancreatic cancer patients after surgery.
What could go wrong
This is a mid-stage trial with 288 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue and digestive issues, and the benefit over chemotherapy alone is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.